Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study.

Plain-language guide to PMID 24026893 (2013): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 119 women, hyperparathyroidism.

Key Facts

PMID: 24026893
Journal: European journal of endocrinology
Year: 2013
Study type: Randomized Controlled Trial
Authors: Norenstedt S et al. (8 authors)
DOI: 10.1530/EJE-13-0547
Registered trial: NCT00982722

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism.

To analyze the vitamin D status and indices of the metabolic syndrome in PHPT patients and the effect of vitamin D supplementation after parathyroid adenomectomy (PTX).

Who Took Part

The abstract describes 119 women taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Double-blinded, randomized clinical trial (ClinicalTrials.gov identifier: NCT00982722) performed at Karolinska University Hospital, Sweden, April 2008 to November 2011.

Changes in metabolic profile and ambulatory blood pressure (BP) were analyzed.

Main outcome measures were changes in metabolic factors, BP, and body composition.

What Was Measured

The subject headings attached to it are Blood Pressure, Blood Pressure Monitoring, Ambulatory, Body Composition, Calcium Carbonate, Cholecalciferol, Hyperparathyroidism, Primary and Insulin Resistance.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 119 women in people with hyperparathyroidism.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (European journal of endocrinology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.